HAART（高效抗逆转录病毒疗法）后免疫无应答状态是目前西医艾滋病治疗的难点。接受HAART治疗后，血浆病毒载量较长时间控制在测不出的水平，但仍有约5%-30%的患者CD4+T淋巴细胞数量未出现显著增长，且此类患者并发机会性感染及死亡风险显著增加。中医药多方面多靶点整体调节已在提升HAART后免疫无应答患者免疫功能，改善症状体征等方面展现了初步疗效，但缺乏对疗效机制深入探讨。本项目采用流式细胞术及Toll样受体信号转导基因芯片等方法，通过对HAART后免疫无应答患者中医药治疗前后T细胞免疫活化分子及Toll样受体信号通路的检测，评价益气健脾颗粒对HAART后免疫无应答患者CD细胞亚群和TLR信号通路的可能影响及上述两者与CD4+T淋巴细胞计数、HIVVL、临床症状体征的相关性分析，揭示该药干预HAART后免疫无应答的疗效机制，为中医药治疗HIV/AIDS提供新的思路和疗效评价指标。

Non-immune response after receiving HAART therapy is a tricky problem puzzled western AIDS treatment, under the premise of ensuring good adherence after receiving HAART therapy, plasma viral load could get undetectable longer control level, but there are still about 5% -30% CD4 + T lymphocytes in patients with no significant growth appears.Traditional Chinese medicine with its multi-target overall regulation has demonstrated preliminary efficacy of improving the immune function and clinical symptoms and signs in patients with no immune response after receiving HAART therapy, but lack of research on deep efficacy mechanism.This project uses flow cytometry and Toll-like receptor signal transduction gene chips methods, through comparison of T cell immune activation molecules and Toll-like receptor signaling pathway between non-immune response patients receiving HAART therapy and HIV-negative healthy subjects, to evaluate abnormal immune response and characteristics of TLR signaling pathways in patients with non-immune response status. This project also compares T cell immune activation molecules and Toll-like receptor signaling pathway between non-immune response patients receiving HAART therapy pre and post traditional Chinese medicine intervention, to evaluate effects of Yiqijianpi Granule on CD cell subtype and TLR signaling pathways, and the correlation between CD cell subtype and TLR signaling pathways and CD4 + T lymphocyte count, HIVVL , clinical symptoms and signs. To reveal the efficacy mechanism of traditional Chinese medicine intervention on non-immune response patients receiving HAART therapy, providing new ideas and efficacy evaluation for Chinese medicine treatment for HIV/AIDS.